Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul;135(7):808-809.
doi: 10.1016/j.amjmed.2022.02.041. Epub 2022 Mar 17.

Cautious Optimism and Considerations for Health Providers and Patients: Oral Antiviral for Early Treatment of High-Risk Patients and Vaccines for Prevention of COVID-19

Jennifer Caceres  1 , Dennis G Maki  2 , Charles H Hennekens  3
Affiliations
Editorial

Cautious Optimism and Considerations for Health Providers and Patients: Oral Antiviral for Early Treatment of High-Risk Patients and Vaccines for Prevention of COVID-19

Jennifer Caceres et al. Am J Med. 2022 Jul.
No abstract available

PubMed Disclaimer

References

    1. FDA News Release. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19.... Accessed February 2, 2022.
    1. The COVID-19 Treatment Guidelines Panel. Statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. Available at:https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-th.... Accessed February 2, 2022.
    1. FDA News Release. Coronavirus (COVID-19) update: FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults. Available at:https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19.... Accessed February 2, 2022.
    1. Centers for Disease Control and Prevention (CDC). Influenza antiviral drug resistance. Available at: https://www.cdc.gov/flu/treatment/antiviralresistance.htm. Accessed February 2, 2022.
    1. Wainberg MA, Brenner BG, Turner D. Changing patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 2005;49(5):1671–1678. doi: 10.1128/AAC.49.5.1671-1678.2005. - DOI - PMC - PubMed

Publication types